Navigation Links
Antibiotics Don't Prevent Future Urinary Tract Infections, May,Cause Resistance in Future Infections

PHILADELPHIA, July 10, 2007 /PRNewswire-USNewswire/ -- After a first childhood urinary tract infection (UTI), daily antibiotics may not prevent another such infection, and may actually increase the risk that the next urinary tract infection is caused by resistant bacteria, according to a new study in the July 11 issue of the Journal of the American Medical Association.

In the first large study of children diagnosed with UTI in a primary care pediatric setting, researchers from The Children's Hospital of Philadelphia reviewed the electronic health records of 74,974 children with at least two clinic visits in The Children's Hospital of Philadelphia's pediatric healthcare network between July 2001 and May 2006. The researchers found that 611 children had a first urinary tract infection and 83 had a recurrent UTI. Children between ages three and five, Caucasians, and those with severe vesicoureteral reflux had the highest risk of recurrent UTI. Receiving a daily dose of preventive antibiotics was not associated with a lower risk of recurrent UTI.

"The majority of children with first UTI were female, Caucasian and two through six years old. Most did not have an imaging study performed and did not receive daily antibiotics to prevent infections," said Patrick Conway, M.D. M.Sc., primary investigator of the study. "We found that daily antibiotic treatment was not associated with a decreased risk of recurrent UTIs, but was associated with an increased risk of resistant infections." Currently at Cincinnati Children's Hospital Medical Center, Dr. Conway conducted the research while at The Children's Hospital of Philadelphia and a Robert Wood Johnson Clinical Scholar at the University of Pennsylvania.

"More definitive studies, such as clinical trials, are needed to look at this issue," said Ron Keren, M.D., M.P.H., a general pediatrician at The Children's Hospital of Philadelphia and senior author on
'"/>




Page: 1 2 3

Related medicine technology :

1. Targanta Reports Improved Ability of Oritavancin to Stop Bacteria Growth In Vitro Compared With Other Glycopeptide Antibiotics
2. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
3. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
4. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
5. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
6. Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of Blindness in Premature Infants
7. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
8. At the 2007 Alzheimers Association International Conference on the Prevention of Dementia - Neurochems U.S. Principal Investigator Presents Update on Tramiprosate (Alzhemed)
9. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
10. New Research Confirms the Benefit of Extended-Release Dipyridamole Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk Patients
11. Investigation Findings, Corroborated by Empirical Evidence of the Schisandra Berry as Cardio-Tonic in Traditional Chinese Medicine for Hundreds of Years, Support the Use of Schisandrin B in the Prevention and Treatment of IHD
Post Your Comments:
(Date:7/30/2015)... , July 30, 2015 Eisai Inc. announced ... the United States , European Union and ... and MHLW, respectively) for eribulin, for the treatment of ... received prior chemotherapy for advanced or metastatic disease. ... from a pivotal global Phase 3 clinical trial (Study ...
(Date:7/30/2015)... 2015 Future Market Insights (FMI) ... Glucose Monitoring Systems Market: Global Industry Analysis and Opportunity ... global continuous glucose monitoring systems market was valued at ... reach US$ 788.4 Mn by 2020, registering a CAGR ... Global continuous glucose monitoring systems market is ...
(Date:7/30/2015)... , July 30, 2015  Medimetriks Pharmaceuticals, Inc. ... second Phase III clinical study for Ozenoxacin, a ... Medimetriks owns the exclusive U.S. rights to Ozenoxacin ... conducted at 44 centers with an emphasis on ... aged 2 months and older with a clinical ...
Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... of Defense Continues Study of Copper as Effective ... Improving Indoor Air Quality, NEW YORK, Nov. ... determining the,antimicrobial effectiveness of copper, brass and bronze ... CDA President Andrew G.,Kireta Sr. Of the ...
... To Enroll 4,000 Patients Worldwide, MENLO PARK, ... it is launching a global Phase III clinical ... novel combination therapy CGT-2168.,The program, which includes the ... at hundreds of sites in the United States, ...
Cached Medicine Technology:Congressional Funds Awarded for Testing of Antimicrobial Copper Metals 2Congressional Funds Awarded for Testing of Antimicrobial Copper Metals 3Cogentus to Launch Phase III Program of Novel Combination Product Designed to Reduce Bleeding Side Effect of Antiplatelet Therapy 2
(Date:7/31/2015)... , ... July 31, 2015 , ... There’s no better ... even when it comes time to cook the next meal, making July the most ... by practicing best grilling tips and recipes. , Make the next cookout different than ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Ticket Down is ... Those looking to catch a new and refreshing show on Broadway, look no ... and achievements including an Obie Award, Outer Critics Circle Award, Drama Desk Award, Lucille ...
(Date:7/31/2015)... ... July 31, 2015 , ... Cosmetic Town has proven itself ... various plastic surgery procedures including, but not limited to, abdominoplasty, blepharoplasty, rhinoplasty and ... Botox and fillers. , Staying up to date with the latest cosmetic ...
(Date:7/31/2015)... ... 2015 , ... “Engage: Don’t Just Age” will be the ... symposiums, hosted by Massachusetts-based Harmony Healthcare International at Foxwoods Resort Casino in ... executives, administrators, directors of nursing, rehabilitation managers and other management and corporate personnel ...
(Date:7/31/2015)... ... July 31, 2015 , ... BioViva USA, Inc. (“BioViva”), ... we treat aging diseases. , BioViva announces it has begun a fundraiser through ... Alzheimer’s Disease (AD) and find a cure. MaxLife will grant 100% of the money ...
Breaking Medicine News(10 mins):Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 3Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 4Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 5Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 6Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 7Health News:Cosmetic Town: Now Providing Interactive And Vital Medical Knowledge 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 3Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3
... Feb. 3 When Americans are asked about the ... Poll, commissioned by the,National Court Appointed Special Advocate (CASA) ... nothing about the experiences of children in,foster care, and ... these,children. When adults do think of children in ...
... and PACS Industry Veteran , Shawn Gibbons ... Compressus, Inc., leaders in healthcare IT systems interoperability ... of Janine Broda to chief marketing officer and ... president and general manager of the MEDxConnect(TM) division.Proven ...
... -- Shengtai,Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ... and distributor of high-quality,pharmaceutical grade glucose products ... invited to make a corporate presentation at ... Conference. , This ...
... are found to slow damage , , TUESDAY, Feb. 3 ... loss caused by Alzheimer,s disease, a new study says. ... University found that insulin acts as a shield that deflects ... responsible for forming memories. , "Therapeutics designed to ...
... Mich., Feb. 3 Perrigo Company,(Nasdaq: PRGO ; TASE) today announced results for its fiscal year 2009 second,quarter and six months that ended December 27, 2008. ... Perrigo Company, (in ... Second Quarter Six Months, ... 2009 2008 2009 ...
... MOUNTAIN VIEW, Calif., Feb. 3 MAP Pharmaceuticals, ... that the waiting period under the Hart-Scott-Rodino Act ... with AstraZeneca has expired, and the agreement is ... AstraZeneca will jointly develop and commercialize UDB, MAP ...
Cached Medicine News:Health News:National CASA Association Aims to Eliminate the Foster Care Stigma 2Health News:Compressus Bolsters Executive Team to Expand Interoperability Market Pioneered by MEDxConnect(TM) 2Health News:Compressus Bolsters Executive Team to Expand Interoperability Market Pioneered by MEDxConnect(TM) 3Health News:Shengtai Pharmaceutical to Present at Roth 21st Annual OC Growth Stock Conference 2Health News:Shengtai Pharmaceutical to Present at Roth 21st Annual OC Growth Stock Conference 3Health News:Insulin May Protect Against Alzheimer's 2Health News:Perrigo Reports Record Second Quarter Sales 2Health News:Perrigo Reports Record Second Quarter Sales 3Health News:Perrigo Reports Record Second Quarter Sales 4Health News:Perrigo Reports Record Second Quarter Sales 5Health News:Perrigo Reports Record Second Quarter Sales 6Health News:Perrigo Reports Record Second Quarter Sales 7Health News:Perrigo Reports Record Second Quarter Sales 8Health News:Perrigo Reports Record Second Quarter Sales 9Health News:Perrigo Reports Record Second Quarter Sales 10Health News:Perrigo Reports Record Second Quarter Sales 11Health News:Perrigo Reports Record Second Quarter Sales 12Health News:Perrigo Reports Record Second Quarter Sales 13Health News:Perrigo Reports Record Second Quarter Sales 14Health News:Perrigo Reports Record Second Quarter Sales 15Health News:Perrigo Reports Record Second Quarter Sales 16Health News:Perrigo Reports Record Second Quarter Sales 17Health News:Perrigo Reports Record Second Quarter Sales 18Health News:MAP Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Unit Dose Budesonide Collaboration with AstraZeneca 2Health News:MAP Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Unit Dose Budesonide Collaboration with AstraZeneca 3Health News:MAP Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Unit Dose Budesonide Collaboration with AstraZeneca 4
... anti-reflux valve is enclosed in ... prevents the valve from being ... sitting or reclining positions. The ... interference free ensuring uninterrupted flow ...
Intermittent catheter - SpeediCath™ is pre-hydrated and ready to use right out of the package. Just open, cath and get on with your life....
The Medtronic® Resting Heart™ System offers a new approach to reducing cardiac surgery morbidity....
This adapter features a female luer on the single leg. A rigid "Y" has two legs with white clamps and terminate with male luers....
Medicine Products: